

Estudio Propio: **EXPERTO EN ANTICONCEPCIÓN REVERSIBLE DE LARGA DURACIÓN (LARC)**

Código Plan de Estudios: **EP50**

Año Académico: **2021-2022**

| <b>ESTRUCTURA GENERAL DEL PLAN DE ESTUDIOS:</b> |              |                |           |                |                    |                      |                  |
|---|--------------|----------------|-----------|----------------|--------------------|----------------------|------------------|
| CURSO   | Obligatorios |                | Optativos |                | Prácticas Externas | TFM/Memoria/Proyecto | Créditos Totales |
|   | Créditos     | Nº Asignaturas | Créditos  | Nº Asignaturas | Créditos           | Créditos             |                  |
| 1º  | 18           | 1              |           |                |                    |                      | 18               |
| 2º  |              |                |           |                |                    |                      |                  |
| 3º  |              |                |           |                |                    |                      |                  |
| <b>ECTS TOTALES</b>                             | <b>18</b>    | <b>1</b>       |           |                |                    |                      | <b>18</b>        |

| <b>PROGRAMA TEMÁTICO:</b>       |       |  |                |          |
|---------------------------------|-------|--|----------------|----------|
| <b>ASIGNATURAS OBLIGATORIAS</b> |       |  |                |          |
| Código Asignatura               | Curso | Denominación   | Carácter OB/OP | Créditos |
| 706275                          | 1     | MANEJO DE ANTICONCEPCIÓN REVERSIBLE DE LARGA DURACIÓN (LARC) | OB             | 18       |

Carácter: OB - Obligatoria; OP – Optativa

## GUÍA DOCENTE

|                                 |   |                |
|---------------------------------|---|----------------|
| Año académico                   | 202-2022  |                |
| Estudio                         | Experto en Anticoncepción Reversible de Larga Duración (EP50) |                |
| Nombre de la asignatura         | MANEJO DE LA ANTICONCEPCIÓN REVERSIBLE DE LARGA DURACIÓN      |                |
| Carácter (Obligatoria/Optativa) | Obligatoria   |                |
| Créditos (1 ECTS=25 horas)      | 18  |                |
| Modalidad (elegir una opción)   |   | Presencial     |
|                                 |   | Semipresencial |
|                                 |   | On-line        |
|                                 | x   | A distancia    |
| Profesor/a responsable          | M <sup>a</sup> Jesús Cancelo Hidalgo                          |                |
| Idioma en el que se imparte     | Castellano  |                |

### PROFESORES IMPLICADOS EN LA DOCENCIA

ESTHER DE LA VIUDA  
EZEQUIEL PÉREZ CAMPOS  
INMACULADA PARRA  
JOSÉ GUTIÉRREZ ALES  
JOSÉ RAMÓN SERRANO NAVARRO  
JOSÉ VTE. GONZÁLEZ NAVARRO  
M<sup>a</sup> JESÚS CANCELO  
MERCEDES ANDEYRO GARCÍA  
SIRA REPOLLÉS LASHERAS

### DISTRIBUCIÓN DE CRÉDITOS (especificar en horas)

|  |     |
|--|-----|
| Número de horas presenciales/on-line asistencia profesor/a | 150 |
| Número de horas de trabajo personal del estudiante         | 300 |
| Total horas  | 450 |

### CONTENIDOS (Temario)

¿QUÉ SON LOS LARC?  
DIU CU. AMPD IM  
DIUS LNG: 5 AÑOS  
DIUS LNG: 3 AÑOS  
IMPLANTE SUBDÉRMICO  
LARC EN ESPAÑA. ENCUESTA SEC Y ENCUESTA SOCIOS SEC SOBRE LARC  
MITOS  
CUMPLIMIENTO Y EFECTIVIDAD  
TIP AND TRICKS

CALIDAD DE VIDA  
CONSENSO DE BELAGIO  
PROGRAMAS DE ASESORAMIENTO EN EL CONSEJO ANTICONCEPTIVO  
ASESORAMIENTO ANTICONCEPTIVO SOBRE LARC  
ANTICONCEPCIÓN SOLO GESTÁGENO  
CRITERIOS DE ELEGIBILIDAD  
PATRÓN DE SANGRADO  
BENEFICIOS  
LARC Y DOBLE MÉTODO  
SITUACIONES ESPECIALES: AU, CANCER, THS, DISCAPACIDAD FÍSICA O INTELECTUAL  
MARCO LEGAL  
ESTRATEGIA NACIONAL DE SSR  
EQUIDAD Y ACCESIBILIDAD  
EXPERIENCIA EN ESPAÑA  
MARCO PROFESIONAL  
PROGRAMAS DE FORMACIÓN Y TALLERES ESPECÍFICOS  
DISMINUCIÓN DEL NÚMERO DE IVES Y PREVENCIÓN DE IVES DE REPETICIÓN

#### **COMPETENCIAS ESPECÍFICAS (indicar un mínimo de tres y máximo de cinco)**

- EL ALUMNO ESTARÁ CAPACITADO/A PARA REALIZAR LA ANAMNESIS, HISTORIA CLÍNICA Y EXPLORACIÓN EN ANTICONCEPCIÓN.
- EL ALUMNO ESTARÁ CAPACITADO/A PARA ASESORAR EN ANTICONCEPCIÓN DE LARGA DURACIÓN REVERSIBLE A LA USUARIA QUE LO DEMANDE EN SU PRÁCTICA CLÍNICA DIARIA.
- EL ALUMNO ESTARÁ CAPACITADO PARA ASESORAR A LA USUARIA SOBRE LOS RIESGOS, BENEFICIOS Y POSIBLES EFECTOS SECUNDARIOS EN ANTICONCEPCIÓN DE LARGA DURACIÓN REVERSIBLE.
- EL ALUMNO ESTARÁ CAPACITADO/A PARA RESOLVER LAS DUDAS MÁS FRECUENTES SOBRE ANTICONCEPCIÓN A LA USUARIA DE ANTICONCEPCIÓN DE LARGA DURACIÓN REVERSIBLE.

#### **EVALUACIÓN**

EXAMEN TIPO TEST

#### **BIBLIOGRAFÍA**

- Gemzell-Danielsson K, Berger C, P GLL. Emergency contraception-mechanisms of action. *Contraception*. 2013;87(3):300-8.
- ACOG Practice bulletin No 121: Long acting reversible contraception: implants and intrauterine devices. *Obstet Gynecol*. 2011;118:184-96.
- Gnoth C, Godehardt D, Godehardt E, et al. Time to pregnancy: results of the German prospective study and impact on the management of infertility. *Hum Reprod*. 2003;18:1959-66.
- Trussell J. Contraceptive failure in the United States. *Contraception*. 2011;83(5):397-404.
- Teal S, Romer E. Awareness of long acting reversible contraception among teens and young adults. *J Adolescent Health*. 2013;52:S35-S39.
- Hubacher D, Grimes DA. Noncontraceptive health benefits of intrauterine devices: a systematic review. *Obstet Gynecol Surv*. 2002;57(2):120-8).
- Castellsague X, Diaz M, Vaccarella S, et al. Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. *The Lancet oncology*. 2011; 12(11):1023-31.
- Brown J, Kives S, Akhtar M. Progestagens and anti-progestagens for pain associated with endometriosis. *Cochrane Database of Systematic Reviews*.

2012(3):CD002122.

American College of Obstetricians and Gynecologists, 2012. Committee opinion no. 539: adolescents and long-acting reversible

contraception: implants and intrauterine devices. *Obstet. Gynecol.* 120, 983-938.

Apter, D., Gemzell-Danielsson, K., Hauck, B., Rosen, K., Zurth, C., 2014. Pharmacokinetics of two low-dose levonorgestrel-releasing

intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies. *Fertil. Steril.* 101, 1656-62 e1-4.

Black, K., Lotke, P., Buhling, K. J., Zite, N. B., Intrauterine contraception for Nulliparous women: Translating Research into Action

Group, 2012. A review of barriers and myths preventing the more widespread use of intrauterine contraception in nulliparous

women. *Eur. J. Contracept. Reprod. Health Care.* 17, 340-350.

Cibula, D., 2008. Women's contraceptive practices and sexual behaviour in Europe. *Eur. J. Contracept. Reprod. Health Care.* 13, 362-375.

Cristobal, I., Neyro, J. L., Lete, I. 2015. The new LNG-releasing IUS: a new opportunity to reduce the burden of unintended pregnancy.

*Eur. J. Obstet. Gynecol. Reprod. Biol.* 190, 58-64.

Equipo Daphne. 2011. VII Encuesta de Anticoncepción en España [Online]. Disponible en:

<http://www.grupodaphne.com> [10 mayo 2015].

Gemzell-Danielsson, K., Schellschmidt, I., Apter, D., 2012. A randomized, phase II study describing the efficacy, bleeding profile, and

safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena. *Fertil. Steril.* 97, 616-22 e1-3.

Mansour, D., Inki, P., Gemzell-Danielsson, K., 2010. Efficacy of contraceptive methods: A review of the literature. *Eur. J. Contracept. Reprod. Health Care.* 15, 4-116.

Reprod. Health Care. 15, 4-116.

Martínez-Benavides, M., Navalón-Bonal, Z., Labrador-Baena, R., 2013. Protocolos SEGO/SEC.

Anticoncepción Intrauterina [on line].

Disponible en: [http://sec.es/descargas/PS\\_Anticoncepcion\\_intrauterina.pdf](http://sec.es/descargas/PS_Anticoncepcion_intrauterina.pdf). [28 abril 2015].

National Institute for Health and Care Excellence. 2013. Long-acting reversible contraception [Online].

Disponible en:

<http://www.nice.org.uk/guidance/cg30/resources/guidance-longacting-reversible-contraception-pdf>. [18 abril 2015].

Nelson, A., Apter, D., Hauck, B., Schmelter, T., Rybowski, S., Rosen, K., Gemzell-Danielsson, K., 2013. Two low-dose levonorgestrel

intrauterine contraceptive systems: a randomized controlled trial. *Obstet Gynecol.* 122, 1205-1213.

Nilsson, C.G., Lahteenmaki, P.L., Luukkainen, T., Robertson, D.N., 1986. Sustained intrauterine release of levonorgestrel over five

years. *Fertil. Steril.* 45, 805-807.

Quesada-Moreno, M. 2013. Protocolos SEGO/SEC. Anticoncepción sólo gestágeno [on line] Disponible en: [http://sec.es/descargas/PS\\_ANTICONCEPCION\\_SOLO\\_GESTAGENOS.pdf](http://sec.es/descargas/PS_ANTICONCEPCION_SOLO_GESTAGENOS.pdf) [27 abril 2015].

Trusell, J., 2004. Contraceptive failure in the United States. *Contraception.* 70, 89-96.

Wiebe, E. R., Trouton, K.J., Dicus, J., 2010. Motivation and experience of nulliparous women using intrauterine contraceptive devices.

*J. Obstet. Gynaecol. Can.* 32, 335-338.

Trusell J. Contraceptive efficacy. 18 ed. En: Hatcher RA, Steward F, eds. Nueva York: 2004;874.

Hatcher R, Trussell J, Nelson A, et al. Contraceptive technology. 20th ed. New York: Ardent Media, Inc; 2011.

ACOG Committee Opinion No. 392. Intrauterine device and adolescents.

- Toivonen J, Luukkainen T, Allonen H. Protective effect of intrauterine release of levonorgestrel on pelvic infection: Three years' comparative experience of levonorgestrel-and copper-releasing intrauterine devices. *Obstet Gynecol.* 1991;77:261-4.
- Mansour D, Gemzell-Danielsson K, Inki P, et al. Fertility after discontinuation of contraception: a comprehensive review of the literature *Contraception.* 2011;84(5):465-77.
- Secura GM, Allsworth JE, Madden T, et al. The Contraceptive CHOICE Project: reducing barriers to long-acting reversible contraception. *Am J Obstet Gynecol.* 2010.
- Blumenthal PD, Dawson L, Hurskainen R. Cost-effectiveness and quality of life associated with heavy menstrual bleeding among women using the levonorgestrel-releasing intrauterine system. *Int J Gynaecol Obstet.* 2011;112(3):171-8
- Calaf J, Lete I, Canals I, et al. Cost-effectiveness analysis in the treatment of heavy menstrual bleeding in Spain. *Eur J Obstet Gynecol Reprod Biol.* 2015;184:24-31.
- Qiu J, Cheng J, Wang Q, et al. Levonorgestrel-releasing intrauterine system versus medical therapy for menorrhagia: a systematic review and meta-analysis. *Med Sci Monit.* 2014;23;20:1700-13.
- Lockhat FB, Emembolu JO, Konje JC. The efficacy, side effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intrauterine administered progestogen (levonorgestrel): a 3 year follow-up. *Hum Reprod.* 2005;20:789-93.
- Vercellini P, Aimi G, Panazza S, et al. A levonorgestrel-releasing intrauterine system for the treatment of dysmenorrhea associated with endometriosis: a pilot study. *Fertil Steril.* 1999;72(3):505-8.
- Abou-Setta AM, Houston B, Al-Inany HG, et al. Levonorgestrel-releasing intrauterine device (LNGIUD) for symptomatic endometriosis following surgery. *Cochrane Database of Systematic Reviews.* 2013(1);CD005072.
- Kim MK, Seong SJ, Lee TS, et al. Treatment with medroxyprogesterone acetate plus levonorgestrel-releasing intrauterine system for early-stage endometrial cancer in young women: single-arm, prospective multicenter study: Korean gynecologic oncology group study (KGOG2009). *Jpn J Clin Oncol.* 2012;42:1215-8.
- Bragheto AM, Caserta N, Bahamondes L, et al. Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging. *Contraception.* 2007;76:195-9.
- Sheng J, Zhang WY, Zhang JP, et al. The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. *Contraception.* 2009;79:189-93.
- Gallos ID, Shehmar M, Thangaratinam S, et al. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. *Am J Obstet Gynecol* 2012;207:266.e1-12.

#### POSIBLE ADAPTACIÓN CURRICULAR POR CAUSA DE FUERZA MAYOR (COVID-19, ETC.)